Research Focus: MET Pathway and MET-Inhibiting Anticancer Agents

Ravi Salgia, MD, provides expert perspective on results of studies of MET-targeted agents being evaluated in a variety of tumor types.
Ravi Salgia, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: July 27, 2012 Expiration: July 26, 2013

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Refer patients to clinical trials of agents targeting the MET pathway for which they may be eligible
  • Explain to colleagues the MET pathway’s role in oncogenesis and the mechanism of action of agents that target it
  • Consider how recent late-phase clinical trial data from agents targeting the MET pathway might be integrated in patient management

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
Genentech BioOncology
Exelixis

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Ravi Salgia, MD

Director of Thoracic Oncology Program
Vice Chair for Translational Research

University of Chicago
Chicago, Illinois

Ravi Salgia, MD, has no significant financial relationships to disclose.

Staff

Andrew D. Bowser, ELS, CCMEP

Editorial Director, Hematology/Oncology

Andrew D. Bowser, ELS, CCMEP, has no significant financial relationships to disclose.
Katherine L. DeYoung, PhD

Editorial Contributor

Katherine L. DeYoung, PhD, has no significant financial relationships to disclose.
Wilma Guerra, ELS

Managing Editor

Wilma Guerra, ELS, has no significant financial relationships to disclose.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no significant financial relationships to disclose.
Edward King, MA

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no significant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no significant financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; Patricia Staples, MSN, NP-C, CCRN and Gordon West, PhD, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematology and oncology researchers, clinicians, and other healthcare professionals.

Goal

The goal of this activity is to increase participants’ understanding of the potential clinical utility of agents targeting MET.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 27, 2012, through July 26, 2013:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Results from the phase I/II study of TAK-788 in previously treated NSCLC with EGFR exon 20 insertions, from ASCO 2019 as reported by CCO

Released: June 11, 2019

Phase III TITAN trial of apalutamide + ADT for patients with metastatic castration-sensitive prostate cancer, as reported by CCO from ASCO 2019.

Released: June 7, 2019

Solange Peters, MD, PhD, discusses key lung cancer presentations from the 2019 European Lung Cancer Congress (ELCC 2019) from Clinical Care Options.

Solange Peters, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: June 6, 2019 Expiration: June 5, 2020

Real-world analysis of outcomes with checkpoint inhibitors in advanced NSCLC patients with vs without autoimmune disease, as reported by CCO from ASCO 2019

Released: June 6, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?